GeneDx Holdings Corp. Payments to Acquire Marketable Securities
GeneDx Holdings Corp. (WGS) reported Payments to Acquire Marketable Securities of $29.07 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-03
- GeneDx Holdings Corp. payments to acquire marketable securities for the quarter ending 2026-06-30 was $8.89M, a 34.46% decline year-over-year.
- GeneDx Holdings Corp. payments to acquire marketable securities for the quarter ending 2026-03-31 was $20.18M, a 17.25% increase year-over-year.
- GeneDx Holdings Corp. payments to acquire marketable securities for the quarter ending 2025-12-31 was $19.14M, a 40.98% increase year-over-year.
- GeneDx Holdings Corp. payments to acquire marketable securities for the quarter ending 2025-09-30 was $5.76M, a 75.30% decline year-over-year.
- GeneDx Holdings Corp. payments to acquire marketable securities for fiscal 2025 was $55.68M, a 16.03% decline from fiscal 2024.
- GeneDx Holdings Corp. payments to acquire marketable securities for fiscal 2024 was $66.30M, a 39.09% increase from fiscal 2023.
- GeneDx Holdings Corp. payments to acquire marketable securities for fiscal 2023 was $47.67M.
- GeneDx Holdings Corp. payments to acquire marketable securities for fiscal 2022 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $29.07M 10-Q · filed 2026-08-03 | $48.21M derived: sum of 3 quarters · filed 2026-08-03 | $53.97M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $20.18M 10-Q · filed 2026-05-04 | $39.32M derived: sum of 2 quarters · filed 2026-05-04 | $45.08M derived: sum of 3 quarters · filed 2026-05-04 | $58.64M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $19.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $24.91M derived: sum of 2 quarters · filed 2026-02-23 | $38.47M derived: sum of 3 quarters · filed 2026-08-03 | $55.68M 10-K · filed 2026-02-23 |
| 2025-09-30 | $5.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $19.33M derived: sum of 2 quarters · filed 2026-08-03 | $36.53M 10-Q · filed 2025-10-28 | $50.11M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $13.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $30.77M 10-Q · filed 2026-08-03 | $44.35M derived: sum of 3 quarters · filed 2026-08-03 | $67.69M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $17.21M 10-Q · filed 2026-05-04 | $30.79M derived: sum of 2 quarters · filed 2026-05-04 | $54.13M derived: sum of 3 quarters · filed 2026-05-04 | $78.34M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $13.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $36.92M derived: sum of 2 quarters · filed 2026-02-23 | $61.13M derived: sum of 3 quarters · filed 2026-02-23 | $66.30M 10-K · filed 2026-02-23 |
| 2024-09-30 | $23.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $47.56M derived: sum of 2 quarters · filed 2025-10-28 | $52.73M 10-Q · filed 2025-10-28 | $56.46M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $24.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | $29.38M 10-Q · filed 2025-07-29 | $33.12M derived: sum of 3 quarters · filed 2026-02-23 | $77.05M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $5.17M 10-Q · filed 2025-04-30 | $8.90M derived: sum of 2 quarters · filed 2026-02-23 | $52.84M derived: sum of 3 quarters · filed 2026-02-23 | $52.84M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $3.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $47.67M derived: sum of 2 quarters · filed 2026-02-23 | $47.67M derived: sum of 3 quarters · filed 2026-02-23 | $47.67M 10-K · filed 2026-02-23 |
| 2023-09-30 | $43.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $43.94M derived: sum of 2 quarters · filed 2024-10-29 | $43.94M 10-Q · filed 2024-10-29 | $43.94M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $0.00 10-Q · filed 2024-07-30 | $0.00 derived: sum of 3 quarters · filed 2024-07-30 | |
| 2023-03-31 | $0.00 10-Q · filed 2024-04-29 | $0.00 derived: sum of 2 quarters · filed 2024-04-29 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $0.00 10-K · filed 2024-02-23 | ||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Privia Health Group, Inc. (PRVA) | United States | $2.477B | 115.52 |
| Pennant Group, Inc. (PNTG) | United States | $1.386B | 39.84 |
| U S PHYSICAL THERAPY INC /NV (USPH) | United States | $1.251B | 32.48 |
| Omada Health, Inc. (OMDA) | United States | $1.207B | 309.08 |
| InnovAge Holding Corp. (INNV) | United States | $1.206B | -635.60 |
| LifeStance Health Group, Inc. (LFST) | United States | $4.510B | 80.86 |
| Strata Critical Medical, Inc. (SRTA) | United States | $0.467B | 11.33 |
| DocGo Inc. (DCGO) | United States | $0.034B | -0.25 |
| VSEE HEALTH, INC. (VSEE) | United States | $0.003B | |
| Agape ATP Corp (ATPC) | $0.002B |